Charles Schwab Investment Management Inc. Has $75.92 Million Holdings in Solventum Co. (NYSE:SOLV)

Charles Schwab Investment Management Inc. lessened its holdings in Solventum Co. (NYSE:SOLV) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,149,198 shares of the company’s stock after selling 36,263 shares during the period. Charles Schwab Investment Management Inc. owned 0.67% of Solventum worth $75,916,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. SBI Securities Co. Ltd. acquired a new stake in shares of Solventum in the 4th quarter valued at $544,000. Jones Financial Companies Lllp lifted its position in Solventum by 14.2% during the 4th quarter. Jones Financial Companies Lllp now owns 3,366 shares of the company’s stock worth $222,000 after acquiring an additional 418 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new position in Solventum during the 4th quarter worth $317,000. Metis Global Partners LLC lifted its position in Solventum by 6.3% during the 4th quarter. Metis Global Partners LLC now owns 4,728 shares of the company’s stock worth $312,000 after acquiring an additional 280 shares during the last quarter. Finally, Terril Brothers Inc. acquired a new position in Solventum during the 4th quarter worth $5,341,000.

Wall Street Analysts Forecast Growth

SOLV has been the subject of a number of research analyst reports. Mizuho boosted their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Bank of America boosted their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Piper Sandler boosted their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. The Goldman Sachs Group boosted their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Finally, Morgan Stanley boosted their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Price Performance

NYSE:SOLV opened at $77.73 on Tuesday. The firm has a market cap of $13.45 billion and a PE ratio of 28.26. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The company’s 50-day moving average price is $73.88 and its two-hundred day moving average price is $70.83.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.